244 related articles for article (PubMed ID: 18836451)
21. Presentation of a self-peptide for in vivo tolerance induction of CD4+ T cells is governed by a processing factor that maps to the class II region of the major histocompatibility complex locus.
Fedoseyeva EV; Tam RC; Orr PL; Garovoy MR; Benichou G
J Exp Med; 1995 Nov; 182(5):1481-91. PubMed ID: 7595218
[TBL] [Abstract][Full Text] [Related]
22. Investigation of peptide involvement in T cell allorecognition using recombinant HLA class I multimers.
Whitelegg AM; Oosten LE; Jordan S; Kester M; van Halteren AG; Madrigal JA; Goulmy E; Barber LD
J Immunol; 2005 Aug; 175(3):1706-14. PubMed ID: 16034111
[TBL] [Abstract][Full Text] [Related]
23. Invariant chain as a vehicle to load antigenic peptides on human MHC class I for cytotoxic T-cell activation.
Wälchli S; Kumari S; Fallang LE; Sand KM; Yang W; Landsverk OJ; Bakke O; Olweus J; Gregers TF
Eur J Immunol; 2014 Mar; 44(3):774-84. PubMed ID: 24293164
[TBL] [Abstract][Full Text] [Related]
24. The antigenic identity of human class I MHC phosphopeptides is critically dependent upon phosphorylation status.
Mohammed F; Stones DH; Zarling AL; Willcox CR; Shabanowitz J; Cummings KL; Hunt DF; Cobbold M; Engelhard VH; Willcox BE
Oncotarget; 2017 Aug; 8(33):54160-54172. PubMed ID: 28903331
[TBL] [Abstract][Full Text] [Related]
25. Phosphorylated self-peptides alter human leukocyte antigen class I-restricted antigen presentation and generate tumor-specific epitopes.
Petersen J; Wurzbacher SJ; Williamson NA; Ramarathinam SH; Reid HH; Nair AK; Zhao AY; Nastovska R; Rudge G; Rossjohn J; Purcell AW
Proc Natl Acad Sci U S A; 2009 Feb; 106(8):2776-81. PubMed ID: 19196958
[TBL] [Abstract][Full Text] [Related]
26. Structures of MART-126/27-35 Peptide/HLA-A2 complexes reveal a remarkable disconnect between antigen structural homology and T cell recognition.
Borbulevych OY; Insaidoo FK; Baxter TK; Powell DJ; Johnson LA; Restifo NP; Baker BM
J Mol Biol; 2007 Oct; 372(5):1123-36. PubMed ID: 17719062
[TBL] [Abstract][Full Text] [Related]
27. Citrullination-dependent differential presentation of a self-peptide by HLA-B27 subtypes.
Beltrami A; Rossmann M; Fiorillo MT; Paladini F; Sorrentino R; Saenger W; Kumar P; Ziegler A; Uchanska-Ziegler B
J Biol Chem; 2008 Oct; 283(40):27189-99. PubMed ID: 18650441
[TBL] [Abstract][Full Text] [Related]
28. Dendritic cell-based immunotherapy for colon cancer using an HLA-A*0201-restricted cytotoxic T-lymphocyte epitope from tumor-associated antigen 90K.
Hee Lee J; Park MS; Hwang JE; Cho SH; Bae WK; Shim HJ; Kim DE; Chung IJ
Cell Mol Immunol; 2013 May; 10(3):275-82. PubMed ID: 23524651
[TBL] [Abstract][Full Text] [Related]
29. Final antigenic Melan-A peptides produced directly by the proteasomes are preferentially selected for presentation by HLA-A*0201 in melanoma cells.
Chapatte L; Servis C; Valmori D; Burlet-Schiltz O; Dayer J; Monsarrat B; Romero P; Lévy F
J Immunol; 2004 Nov; 173(10):6033-40. PubMed ID: 15528338
[TBL] [Abstract][Full Text] [Related]
30. Alloreactive cytotoxic T cells provide means to decipher the immunopeptidome and reveal a plethora of tumor-associated self-epitopes.
Kumari S; Wälchli S; Fallang LE; Yang W; Lund-Johansen F; Schumacher TN; Olweus J
Proc Natl Acad Sci U S A; 2014 Jan; 111(1):403-8. PubMed ID: 24344295
[TBL] [Abstract][Full Text] [Related]
31. The landscape of MHC-presented phosphopeptides yields actionable shared tumor antigens for cancer immunotherapy across multiple HLA alleles.
Molvi Z; Klatt MG; Dao T; Urraca J; Scheinberg DA; O'Reilly RJ
bioRxiv; 2023 Feb; ():. PubMed ID: 36798179
[TBL] [Abstract][Full Text] [Related]
32. Specific targeting of a naturally presented osteosarcoma antigen, papillomavirus binding factor peptide, using an artificial monoclonal antibody.
Tsukahara T; Emori M; Murata K; Hirano T; Muroi N; Kyono M; Toji S; Watanabe K; Torigoe T; Kochin V; Asanuma H; Matsumiya H; Yamashita K; Himi T; Ichimiya S; Wada T; Yamashita T; Hasegawa T; Sato N
J Biol Chem; 2014 Aug; 289(32):22035-47. PubMed ID: 24962571
[TBL] [Abstract][Full Text] [Related]
33. Major histocompatibility complex class II+ invariant chain negative breast cancer cells present unique peptides that activate tumor-specific T cells from breast cancer patients.
Chornoguz O; Gapeev A; O'Neill MC; Ostrand-Rosenberg S
Mol Cell Proteomics; 2012 Nov; 11(11):1457-67. PubMed ID: 22942358
[TBL] [Abstract][Full Text] [Related]
34. Identification of two novel HLA-A*0201-restricted CTL epitopes derived from MAGE-A4.
Jia ZC; Ni B; Huang ZM; Tian Y; Tang J; Wang JX; Fu XL; Wu YZ
Clin Dev Immunol; 2010; 2010():567594. PubMed ID: 21350607
[TBL] [Abstract][Full Text] [Related]
35. A structure-based algorithm to predict potential binding peptides to MHC molecules with hydrophobic binding pockets.
Altuvia Y; Sette A; Sidney J; Southwood S; Margalit H
Hum Immunol; 1997 Nov; 58(1):1-11. PubMed ID: 9438204
[TBL] [Abstract][Full Text] [Related]
36. CD8 T-cell recognition of human 5T4 oncofetal antigen.
Smyth LJ; Elkord E; Taher TE; Jiang HR; Burt DJ; Clayton A; van Veelen PA; de Ru A; Ossendorp F; Melief CJ; Drijfhout JW; Dermime S; Hawkins RE; Stern PL
Int J Cancer; 2006 Oct; 119(7):1638-47. PubMed ID: 16646078
[TBL] [Abstract][Full Text] [Related]
37. "Self" to cytotoxic T cells has to be 1,000 or less high affinity nonapeptides per MHC antigen.
Ohno S
Immunogenetics; 1992; 36(1):22-7. PubMed ID: 1375187
[TBL] [Abstract][Full Text] [Related]
38. MHC-peptide-specific antibodies reveal inefficient presentation of an HLA-A*0201-restricted, Melan-A-derived peptide after active intracellular processing.
Held G; Wadle A; Dauth N; Stewart-Jones G; Sturm C; Thiel M; Zwick C; Dieckmann D; Schuler G; Hoogenboom HR; Lévy F; Cerundolo V; Pfreundschuh M; Renner C
Eur J Immunol; 2007 Jul; 37(7):2008-17. PubMed ID: 17559180
[TBL] [Abstract][Full Text] [Related]
39. Fine structural variations of alphabetaTCRs selected by vaccination with natural versus altered self-antigen in melanoma patients.
Wieckowski S; Baumgaertner P; Corthesy P; Voelter V; Romero P; Speiser DE; Rufer N
J Immunol; 2009 Oct; 183(8):5397-406. PubMed ID: 19786555
[TBL] [Abstract][Full Text] [Related]
40. Poor binding of a HER-2/neu epitope (GP2) to HLA-A2.1 is due to a lack of interactions with the center of the peptide.
Kuhns JJ; Batalia MA; Yan S; Collins EJ
J Biol Chem; 1999 Dec; 274(51):36422-7. PubMed ID: 10593938
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
